What is Zacks Research's Forecast for Prothena Q1 Earnings?

Key Points

• Zacks Research has revised its Q1 2026 earnings per share (EPS) estimate for Prothena (NASDAQ: PRTA) to ($0.88), up from a previous estimate of ($0.92).
• The biotechnology company reported a Q2 earnings miss with EPS of ($1.86), falling short of the consensus estimate of ($1.11), alongside revenues of $4.42 million compared to analyst expectations of $5.36 million.
• Prothena has a mix of ratings from analysts, with four maintaining a "Buy" rating and an average target price of $19.75 despite recent stock fluctuations.

Prothena Corporation plc (NASDAQ:PRTA - Free Report) - Stock analysts at Zacks Research raised their Q1 2026 earnings per share estimates for Prothena in a report issued on Thursday, September 11th. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.88) per share for the quarter, up from their prior estimate of ($0.92). The consensus estimate for Prothena's current full-year earnings is ($4.04) per share. Zacks Research also issued estimates for Prothena's Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($2.59) EPS, Q1 2027 earnings at ($0.87) EPS, Q2 2027 earnings at ($0.80) EPS and FY2027 earnings at ($1.93) EPS.

Prothena (NASDAQ:PRTA - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biotechnology company reported ($1.86) EPS for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.75). The firm had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. Prothena had a negative net margin of 2,929.30% and a negative return on equity of 62.17%.

Other analysts have also issued reports about the company. Cantor Fitzgerald restated a "neutral" rating on shares of Prothena in a report on Friday, June 20th. Bank of America restated an "underperform" rating on shares of Prothena in a report on Wednesday, May 28th. Jefferies Financial Group lowered Prothena from a "buy" rating to a "hold" rating and set a $6.00 price target on the stock. in a report on Tuesday, May 27th. Chardan Capital restated a "buy" rating and issued a $18.00 price target on shares of Prothena in a report on Thursday, August 28th. Finally, Oppenheimer lowered Prothena from an "outperform" rating to a "market perform" rating in a report on Tuesday, May 27th. Four investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Prothena has a consensus rating of "Hold" and an average target price of $19.75.

Prothena Trading Down 1.3%

Shares of Prothena stock traded down $0.11 during trading on Monday, reaching $8.07. The stock had a trading volume of 910,675 shares, compared to its average volume of 842,939. The company has a market capitalization of $434.41 million, a price-to-earnings ratio of -1.43 and a beta of -0.04. The stock has a fifty day moving average price of $7.69 and a two-hundred day moving average price of $8.33. Prothena has a 52 week low of $4.32 and a 52 week high of $22.25.

Institutional Trading of Prothena

Several institutional investors and hedge funds have recently bought and sold shares of PRTA. Acadian Asset Management LLC bought a new stake in Prothena during the second quarter worth about $6,176,000. Wellington Management Group LLP raised its stake in Prothena by 22.8% in the fourth quarter. Wellington Management Group LLP now owns 5,130,876 shares of the biotechnology company's stock valued at $71,063,000 after buying an additional 952,088 shares during the period. Rangeley Capital LLC bought a new stake in Prothena in the second quarter valued at approximately $4,342,000. Federated Hermes Inc. raised its stake in Prothena by 116.2% in the second quarter. Federated Hermes Inc. now owns 1,181,087 shares of the biotechnology company's stock valued at $7,169,000 after buying an additional 634,832 shares during the period. Finally, Balyasny Asset Management L.P. bought a new stake in Prothena in the second quarter valued at approximately $3,495,000. Institutional investors own 97.08% of the company's stock.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.